NASDAQ · Health care

Harmony Biosciences Holdings, Inc. (HRMY)

Harmony Biosciences Holdings, Inc. brought in $989.4M of revenue over the twelve months to September 30, 2026, up 19.8% from a year earlier. Net income was $178.6M, a net margin of 18.1%. Operating cash flow minus capital spending left $347.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $647.1M in cash against $149.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.

Watch HRMY in 60 seconds

Price

$33.78

+2.02% on the day · November 9, 2026

52-week range $25.90 to $43.49

Market cap

$2B

Revenue (last 12 months)

$989.4M

+19.8% year on year

Net margin

18.1%

P/E

12.5

on FY2025 diluted EPS

Key facts about Harmony Biosciences Holdings, Inc.

Net worth: Harmony Biosciences Holdings, Inc. has a market value (market cap) of $2B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $868.5M (+21.5% year on year), with net income of $158.7M. Over the 12 months to September 30, 2026: revenue $989.4M, net income $178.6M.
Cash flow: In fiscal 2025 operations brought in $348.2M of cash; after $310K of capital spending, free cash flow was $347.9M.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
Next earnings report: Harmony Biosciences Holdings, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What Harmony Biosciences Holdings, Inc. does

Harmony Biosciences Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HRMY.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$868.5M	$208.5M	$158.7M	$2.71	$347.9M
2024	$714.7M	$190.8M	$145.5M	$2.51	$218.7M
2023	$582M	$192M	$128.9M	$2.13	$219.1M
2022	$437.9M	$120.2M	$181.5M	$2.97	$144.3M
2021	$305.4M	$87.5M	$34.6M	$0.58	$98.3M
2020	$159.7M	$17M	-$36.9M	-$2.48	-$3M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around January 11, 2027.

Estimated from its filing rhythm: 52 weeks after its report of January 12, 2026. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where HRMY ranks in Health care

Revenue$868.5M

#165 of 751 in Health care · Top 22%

Revenue growth+21.5%

#172 of 532 in Health care · Top 32%

Net margin18.3%

#65 of 544 in Health care · Top 12%

Free cash flow margin40.1%

#14 of 490 in Health care · Top 3%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Harmony Biosciences Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 4, 2026
Quarterly report 10-Q · period to September 30, 2026Revenue rose 12% to $268.9M versus the same quarter last year; diluted EPS $0.81 versus $0.87.
November 4, 2026
Quarterly results 8-K
October 30, 2026
Executive or director change 8-K/A
October 27, 2026
Passive stake changed SCHEDULE 13G/A
October 13, 2026
Executive or director change 8-K
August 4, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue rose 30% to $261.3M versus the same quarter last year; diluted EPS $1.28 versus $0.68.
August 4, 2026
Quarterly results 8-K
July 31, 2026
Passive stake (5% or more) SCHEDULE 13G
July 28, 2026
Passive stake changed SCHEDULE 13G/A
July 16, 2026
Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 18, 2026. Insider transactions on SEC

What is HRMY worth? A DCF from its reported cash flow

Insider trades

What the people running Harmony Biosciences Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $3.1M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)

last 90 days

Sold

$3.1M

last 90 days

Net sold

72,406

$3.1M

Date	Insider	What	Shares	Price	Value	Filing
September 18, 2026	Budur KumarCHIEF MEDICAL OFFICER	Exercised options	10,406	$30.69	$319.4K	Form 4
September 18, 2026	Budur KumarCHIEF MEDICAL OFFICER	Exercised options	25,446	$30.27	$770.3K	Form 4
September 18, 2026	Budur KumarCHIEF MEDICAL OFFICER	Soldpre-planned (10b5-1)	35,852	$43.05	$1.5M	Form 4
September 17, 2026	Budur KumarCHIEF MEDICAL OFFICER	Exercised options	400	$30.69	$12.3K	Form 4
September 17, 2026	Budur KumarCHIEF MEDICAL OFFICER	Exercised options	400	$30.27	$12.1K	Form 4
September 17, 2026	Budur KumarCHIEF MEDICAL OFFICER	Soldpre-planned (10b5-1)	800	$43.00	$34.4K	Form 4
September 16, 2026	Budur KumarCHIEF MEDICAL OFFICER	Exercised options	900	$30.69	$27.6K	Form 4
September 16, 2026	Budur KumarCHIEF MEDICAL OFFICER	Exercised options	900	$30.27	$27.2K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns HRMY

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
BlackRock, Inc.13G, passive	12.6%	7,361,888	October 27, 2026
Marshman Fund Trust II13G, passive	10.6%	6,051,120	February 10, 2025
Fmr LLC13G, passive with 1 related filers	5.4%	3,112,812	February 5, 2026
Vanguard Portfolio Management13G, passive	5.08%	2,943,383	July 31, 2026

Latest filings below 5%: The Vanguard Group 0% (March 27, 2026); Antonio J. Gracias 3.2% (November 14, 2025).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 327 managers reported a position.

Holder	Shares	Value	Change on quarter
BlackRock, Inc.	7,101,965	$258.6M	+31,930
Fmr LLC	3,574,115	$130.1M	+416,476
Vanguard Portfolio Management LLC	2,880,489	$104.9M	+166,136
American Century Companies Inc	2,539,512	$92.5M	+434,333
Dimensional Fund Advisors LP	2,393,588	$87.1M	+317,078
Vanguard Capital Management LLC	2,105,053	$76.6M	+2,738
State Street Corp	1,859,322	$67.7M	+74,960
Armistice Capital, LLC	1,564,000	$56.9M	-60,000
Geode Capital Management, LLC	1,442,649	$52.5M	+119,929
Arrowstreet Capital, Limited Partnership	1,312,550	$47.8M	-69,563
Renaissance Technologies LLC	1,195,371	$43.5M	+118,000
Two Sigma Investments, LP	959,136	$34.9M	+225,693
Aqr Capital Management LLC	934,326	$34M	+218,080
Valor Management LLC	818,013	$29.8M	+700,883
Morgan Stanley	733,684	$26.7M	-297,334
UBS Group AG	602,990	$22M	+154,999
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	551,075	$20.1M	-16,040
Invesco Ltd.	528,520	$19.2M	-99,727
Jpmorgan Chase & Co	514,085	$18.2M	-309,428
venBio Partners LLC	472,194	$17.2M	-17,000

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 50,783 shares in total, about $1.7M at the last price.

Holder	Shares	As of
Kapadia SandipCHIEF FINANCIAL OFFICER	24,521	January 26, 2026
Budur KumarCHIEF MEDICAL OFFICER	13,115	September 18, 2026
Dayno Jeffrey M.PRESIDENT, CEO, Director	7,346	January 25, 2026
Zaeske Adam H.CHIEF COMMERCIAL OFFICER	4,327	April 7, 2026
Serafin AndrewCHIEF STRATEGY OFFICER	1,474	January 25, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about HRMY

What does Harmony Biosciences Holdings, Inc. do?

Harmony Biosciences Holdings, Inc. is a company in the Health care sector, listed on NASDAQ as HRMY. Its shares trade on NASDAQ under the ticker HRMY.

What is Harmony Biosciences Holdings, Inc.'s net worth?

Harmony Biosciences Holdings, Inc. has a market value (market cap) of $2B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Harmony Biosciences Holdings, Inc. profitable?

Yes. Over the twelve months to September 30, 2026 it reported net income of $178.6M on revenue of $989.4M, a net margin of 18.1%.

How much revenue does Harmony Biosciences Holdings, Inc. make?

Over the twelve months to September 30, 2026 Harmony Biosciences Holdings, Inc. reported revenue of $989.4M. That is 19.8% more than a year earlier.

When did Harmony Biosciences Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.

When is Harmony Biosciences Holdings, Inc.'s next earnings report?

Harmony Biosciences Holdings, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

ZBIO

Zenas BioPharma, Inc.

AGIO

Agios Pharmaceuticals, Inc.

GENB

Generate Biomedicines, Inc.

KARD

Kardigan, Inc.

SRPT

Sarepta Therapeutics, Inc.

DMRA

Damora Therapeutics, Inc.

Compare HRMY with

Compare HRMY with any company

Follow HRMY

Get an email when Harmony Biosciences Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values Harmony Biosciences Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.